<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2003-9-1-21-25</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-868</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Влияние длительной терапии эпросартаном на структурно-функциональное состояние сердца и крупных сосудов и вегетативную регуляцию кровообращения у больных гипертонической болезнью</article-title><trans-title-group xml:lang="en"><trans-title>Impact of long-term therapy with eprosartan on the structural and functional state of the heart and large vessels and on the autonomic regulation of circulation in patients with arterial hypertension</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковлева</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakovleva</surname><given-names>O. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мамонтов</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mamontov</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковлев</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakovlev</surname><given-names>A. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вахрамеева</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vakhromeyeva</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Конради</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Konradi</surname><given-names>A. O.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>СПбГМУ им. акад. И.П.Павлова; Институт сердечно-сосудистых заболеваний, Санкт-Петербург</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2003</year></pub-date><pub-date pub-type="epub"><day>28</day><month>02</month><year>2003</year></pub-date><volume>9</volume><issue>1</issue><fpage>21</fpage><lpage>25</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Яковлева О.И., Мамонтов О.В., Яковлев А.Н., Вахрамеева Н.В., Конради А.О., 2003</copyright-statement><copyright-year>2003</copyright-year><copyright-holder xml:lang="ru">Яковлева О.И., Мамонтов О.В., Яковлев А.Н., Вахрамеева Н.В., Конради А.О.</copyright-holder><copyright-holder xml:lang="en">Yakovleva O.I., Mamontov O.V., Yakovlev A.N., Vakhromeyeva N.V., Konradi A.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/868">https://htn.almazovcentre.ru/jour/article/view/868</self-uri><abstract><p>С целью изучения влияния эпросартана на ремоделирование сердца и крупных сосудов, дисфункцию эндотелия и состояние вегетативной регуляции кровообращения у больных гипертонической болезнью в исследование были включены 13 пациентов. Эхокардиографическое исследование с допплерографией и оценкой диастолической функции левого желудочка проводили на аппарате Vingmed CFM-800, на этом же приборе, но с применением датчика 7,5 МГц, определяли толщину комплекса интима-медиа сонных артерий и диаметр плечевой артерии в пробе с реактивной гиперемией. Вегетативный баланс оценивали методом спектрального анализа вариабельности сердечного ритма. Также тестировался кардиопульмональный компонент барорефлекса. Через 24 нед терапии эпросартаном в дозе 600 мг в сутки нормализация артериального давления была достигнута у 3 пациентов. Исключены из исследования 2 больных в связи с отсутствием эффекта. У остальных больных антигипертензивный эффект был неполным. Масса миокарда левого желудочка снизилась на 10,8%, также отмечено увеличение степени расширения плечевой артерии в пробе с реактивной гиперемией. Параметры вариабельности сердечного ритма достоверно не изменялись, отмечена тенденция к ухудшению барорефлекса. Таким образом, длительная терапия эпросартаном приводит к улучшению структурно-функционального состояния сердца и сосудов и не оказывает влияния на вегетативную регуляцию кровообращения.</p></abstract><trans-abstract xml:lang="en"><p>To examine the effects of eprosartan on the remodelling of the heart and large vessels, on endothelial dysfunction and autonomic circulatory regulation in patients with hypertensive disease, thirteen patients were included into the study: Doppler echocardiographic study and evaluation of left ventricular diastolic function were performed on a Vingmed CFM800 apparatus: the thickness of the carotid intima-media complex and the diameter of the brachial artery were determined on the same apparatus using a 7.5-MHz transducer in the reactive hyperemia test. Automatic balance was evaluated by the spectral assay of cardiac rhythm variations. The cardiopulmonary component of baroreflex was also tested. Blood pressure normalized in 3 patients following 24 weeks of therapy with eprosartan in a daily dose of 600 mg. Two patients were excluded due to therapeutic inefficiency. In the remaining patients, the antihypertensive effect was incomplete. The mass of the left myocardial myocardium decreased by 10.8%. there was an increase in brachial arterial dilatation in the reactive hyperemia test. The variations of cardiac rhythm were not significantly changed, the baroreflex tended to be decreased. Thus, long-term eprosartan therapy improves the structural and functional state of the heart and vessels and fails to affect the autonomic regulation of circulation.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>гипертрофия левого желудочка</kwd><kwd>ремоделирование крупных сосудов</kwd><kwd>эндотелиальная функция</kwd><kwd>вегетативная регуляция сердца и сосудов</kwd><kwd>эпросартан</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>left ventricular hypertrophy</kwd><kwd>remodelling of large vessels</kwd><kwd>endothelial function</kwd><kwd>autonomic cardiovascular regulation</kwd><kwd>eprosartan</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Dablof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in tbe Losartan Intervention For Endpoint reduction in hypertension study (UFE): a randomized trial against atenolol. Lancet2002; 359:995- I 003.</mixed-citation><mixed-citation xml:lang="en">Dablof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in tbe Losartan Intervention For Endpoint reduction in hypertension study (UFE): a randomized trial against atenolol. Lancet2002; 359:995- I 003.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Oblstein EH, Brooks DP, Feuerslein GZ et al. Inhibition of sympathetic outflow by tbe angiotensin Il receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55:244-51.</mixed-citation><mixed-citation xml:lang="en">Oblstein EH, Brooks DP, Feuerslein GZ et al. Inhibition of sympathetic outflow by tbe angiotensin Il receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55:244-51.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Brooks D, Oblstein E, Ruffolo R. Pharmacology of eprosartan - an angiotensin II receptor antagonist: exploring hypothesisfrom clinical trials. Am Heart J 1999; 138: S247-S251.</mixed-citation><mixed-citation xml:lang="en">Brooks D, Oblstein E, Ruffolo R. Pharmacology of eprosartan - an angiotensin II receptor antagonist: exploring hypothesisfrom clinical trials. Am Heart J 1999; 138: S247-S251.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization - International Society of Hypertension guidelines for the management of hypertension J Hypertens, 1999; 17- 151-83.</mixed-citation><mixed-citation xml:lang="en">World Health Organization - International Society of Hypertension guidelines for the management of hypertension J Hypertens, 1999; 17- 151-83.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации. Клинические рекомендации. Клин. фармакол. и тер. 2000; 9:5-30.</mixed-citation><mixed-citation xml:lang="en">Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации. Клинические рекомендации. Клин. фармакол. и тер. 2000; 9:5-30.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">De Gasparo M1 Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotenzin-converting enzymeb Pharmacol Toxicol 1998;82:257-71.</mixed-citation><mixed-citation xml:lang="en">De Gasparo M1 Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotenzin-converting enzymeb Pharmacol Toxicol 1998;82:257-71.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cuspidi C, Muiesan ML, Valagussa L. Comparative effects of candesartm and enalapril on left ventricular hypertrophy in patients with essential hypertension: tbe candesartan assessment in the treatement of cardiac hypertrophy (CATCH) study.J Hypertens 2002 Nov; 20 (I I): 2293-300.</mixed-citation><mixed-citation xml:lang="en">Cuspidi C, Muiesan ML, Valagussa L. Comparative effects of candesartm and enalapril on left ventricular hypertrophy in patients with essential hypertension: tbe candesartan assessment in the treatement of cardiac hypertrophy (CATCH) study.J Hypertens 2002 Nov; 20 (I I): 2293-300.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Schiffrin EL, Hayoz D. Angiotensin U Receptor antagonists. Eds. M. Epstein, HR. Brunner. Philadelphia: Hanley Belfus INC 2001; 279-89.</mixed-citation><mixed-citation xml:lang="en">Schiffrin EL, Hayoz D. Angiotensin U Receptor antagonists. Eds. M. Epstein, HR. Brunner. Philadelphia: Hanley Belfus INC 2001; 279-89.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Taddei S, Virdis A, Chiadcnii L, Salvetti A. The pivotal role of endothelium in hypertension. Medicographia 1999; Issue 59; 21:22-9-</mixed-citation><mixed-citation xml:lang="en">Taddei S, Virdis A, Chiadcnii L, Salvetti A. The pivotal role of endothelium in hypertension. Medicographia 1999; Issue 59; 21:22-9-</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Iwatsubo H, Nagano M, Sakai T et al. Converting Enzyme Inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension 1997; 29 (Pt2): 286-90.</mixed-citation><mixed-citation xml:lang="en">Iwatsubo H, Nagano M, Sakai T et al. Converting Enzyme Inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension 1997; 29 (Pt2): 286-90.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Rajagopalan S, Harrison D. Reversing endothelial dysfunction with] ACE inhibitors. A new TRENDb Circulation 1996; 94:240-3.</mixed-citation><mixed-citation xml:lang="en">Rajagopalan S, Harrison D. Reversing endothelial dysfunction with] ACE inhibitors. A new TRENDb Circulation 1996; 94:240-3.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.</mixed-citation><mixed-citation xml:lang="en">Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Dohn K, GravehorstJSJarlov HV. Volume recorder during junctional states. Reports of tbe Steno Memorial Hospital and tbe Nordisk Insulin Laboratorium. Copenhagen 1956; 6:140.</mixed-citation><mixed-citation xml:lang="en">Dohn K, GravehorstJSJarlov HV. Volume recorder during junctional states. Reports of tbe Steno Memorial Hospital and tbe Nordisk Insulin Laboratorium. Copenhagen 1956; 6:140.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Скардс ЯВ., Витолс АЯ. Гибкий онкометр для определения объема кровотока предплечья и голени методам венозной окклюзионной плетизмографии. Физиол.журн.СССР 1974; 10:16-8.</mixed-citation><mixed-citation xml:lang="en">Скардс ЯВ., Витолс АЯ. Гибкий онкометр для определения объема кровотока предплечья и голени методам венозной окклюзионной плетизмографии. Физиол.журн.СССР 1974; 10:16-8.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Stevens PM, Lamb LE. Effect of Lower Body Negative Pressure on the Cardiovascular System, Am J Cardiol 1965; 16:506-15-</mixed-citation><mixed-citation xml:lang="en">Stevens PM, Lamb LE. Effect of Lower Body Negative Pressure on the Cardiovascular System, Am J Cardiol 1965; 16:506-15-</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Elliot WJ et al. Double-blind comparision of eprosartan and enalapril on cough and blood pressure. J Hum Hypertens 1999; 13:413-7.</mixed-citation><mixed-citation xml:lang="en">Elliot WJ et al. Double-blind comparision of eprosartan and enalapril on cough and blood pressure. J Hum Hypertens 1999; 13:413-7.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Оганов PT, Небиеридзе AB. Метаболические эффекты блокаторов рецепторов ангиотензина II. Кардиология, 2002; 42:35-9</mixed-citation><mixed-citation xml:lang="en">Оганов PT, Небиеридзе AB. Метаболические эффекты блокаторов рецепторов ангиотензина II. Кардиология, 2002; 42:35-9</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Rupp H, Jager B. The renin - angiotensin system and sympathetic nervous „system in hypertension and congestive heart failure: implicationsfor therapeutic interventions.! Clin Basic Cardiol 2001; 4:47-51.</mixed-citation><mixed-citation xml:lang="en">Rupp H, Jager B. The renin - angiotensin system and sympathetic nervous „system in hypertension and congestive heart failure: implicationsfor therapeutic interventions.! Clin Basic Cardiol 2001; 4:47-51.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Thurmann PAAngiotensin Il antagonism and the heart: valsartan in left ventricular hypertrophy. J Cardiovasc Pharmacol 1999; 33 (I): 33 -6.</mixed-citation><mixed-citation xml:lang="en">Thurmann PAAngiotensin Il antagonism and the heart: valsartan in left ventricular hypertrophy. J Cardiovasc Pharmacol 1999; 33 (I): 33 -6.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Yoriucbi M, Akishita M, Dzau V. Recentprogress in angiotensin II type 2 receptor research in cardiovascular system Hypertension 1999; 33:613-21.</mixed-citation><mixed-citation xml:lang="en">Yoriucbi M, Akishita M, Dzau V. Recentprogress in angiotensin II type 2 receptor research in cardiovascular system Hypertension 1999; 33:613-21.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sigare HM, Caret RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 35’-monophosphate and ATI receptor-mediated prostaglandin E2 production in conscious rats.J Clin Invest 1996; 97:1978-82.</mixed-citation><mixed-citation xml:lang="en">Sigare HM, Caret RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 35’-monophosphate and ATI receptor-mediated prostaglandin E2 production in conscious rats.J Clin Invest 1996; 97:1978-82.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Schiffrin EL. Effects of angiotensin on vascular health and the importance of selective angiotensin receptor. International Forum cm Angiotensin 11 Receptor Antagonism, 2 -nd. Monte-Carlo 2001; Abstract Book: 12.</mixed-citation><mixed-citation xml:lang="en">Schiffrin EL. Effects of angiotensin on vascular health and the importance of selective angiotensin receptor. International Forum cm Angiotensin 11 Receptor Antagonism, 2 -nd. Monte-Carlo 2001; Abstract Book: 12.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Dominiczak AF, Berry C, Brosnan MJ et al. Angiotensin 11 and superoxide formation in human arteries. International Forum on Angiotensin II Receptor Antagonism, 2-nd. Monte-Carlo 2001,Abstract Book: 5</mixed-citation><mixed-citation xml:lang="en">Dominiczak AF, Berry C, Brosnan MJ et al. Angiotensin 11 and superoxide formation in human arteries. International Forum on Angiotensin II Receptor Antagonism, 2-nd. Monte-Carlo 2001,Abstract Book: 5</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lahera V. Angiotensin 11 and atberoslerosis. International Forum on Angiotensin Il Receptor Antagonism, 2-nd. Monte-Carlo 2001 Abstract Book: 5</mixed-citation><mixed-citation xml:lang="en">Lahera V. Angiotensin 11 and atberoslerosis. International Forum on Angiotensin Il Receptor Antagonism, 2-nd. Monte-Carlo 2001 Abstract Book: 5</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Балахонова TB, Погорелова OA, Ачыджанова ХГ. и др. Неинвазивное определение функции эндотелия у больных гипертонической болезнью в сочетании с гиперхолестеринемией. Тер. арх. 1998; 4:15—9·</mixed-citation><mixed-citation xml:lang="en">Балахонова TB, Погорелова OA, Ачыджанова ХГ. и др. Неинвазивное определение функции эндотелия у больных гипертонической болезнью в сочетании с гиперхолестеринемией. Тер. арх. 1998; 4:15—9·</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Иванова O.B., Балахонова Τ.Β., Соболева Г,Н. и др. Состояние эндотелий-зависимой вазодилатации плечевой артерии у больных гипертонической болезнью, оцениваемое с помощью ультразвука высокого разрешения. Кардиология, 1997; 7:41-6.</mixed-citation><mixed-citation xml:lang="en">Иванова O.B., Балахонова Τ.Β., Соболева Г,Н. и др. Состояние эндотелий-зависимой вазодилатации плечевой артерии у больных гипертонической болезнью, оцениваемое с помощью ультразвука высокого разрешения. Кардиология, 1997; 7:41-6.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Celermajer DS, Sorensen KE, Georgakopoulos Detal Cigarette smoking is associated with dose - related and potentially reversible impairment of endothelium - dependent dilation in healthy young adults. Circulation 1993; 88: 2149-55-</mixed-citation><mixed-citation xml:lang="en">Celermajer DS, Sorensen KE, Georgakopoulos Detal Cigarette smoking is associated with dose - related and potentially reversible impairment of endothelium - dependent dilation in healthy young adults. Circulation 1993; 88: 2149-55-</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Paolisso G, Tagliamonte MR, Gambardella Ą ManzeUa D, Gualdiero P, Varricchio G, Verza M, Varricchio M. Losartan mediated improvement in insulin action is mainly dueto an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients.J Hum Hypertens 1997 May ; 116: 307-2.</mixed-citation><mixed-citation xml:lang="en">Paolisso G, Tagliamonte MR, Gambardella Ą ManzeUa D, Gualdiero P, Varricchio G, Verza M, Varricchio M. Losartan mediated improvement in insulin action is mainly dueto an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients.J Hum Hypertens 1997 May ; 116: 307-2.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Newby DE, Goodfield NE, Flapan AD, Boon NA, Fox KA, Webb DJ. Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II.Heart 1998 Aug; 116:134—40.</mixed-citation><mixed-citation xml:lang="en">Newby DE, Goodfield NE, Flapan AD, Boon NA, Fox KA, Webb DJ. Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II.Heart 1998 Aug; 116:134—40.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Head GA, Saigusa T, Mayorov DN. Angiotensin and baroreflex control of tbe circulation. Braz J Med Biol Res 2002 Sep; 35:1047-59-31. Veelken R, Hilgers KF, Scrogin KE, Mann JF, Schmieder RE. Endogenous angiotensin Il and the reflex response to stimulation of cardiopulmonary serotonin 5HT3 receptors.Br J Pharmacol 1998 Dec; 125:1761-7.</mixed-citation><mixed-citation xml:lang="en">Head GA, Saigusa T, Mayorov DN. Angiotensin and baroreflex control of tbe circulation. Braz J Med Biol Res 2002 Sep; 35:1047-59-31. Veelken R, Hilgers KF, Scrogin KE, Mann JF, Schmieder RE. Endogenous angiotensin Il and the reflex response to stimulation of cardiopulmonary serotonin 5HT3 receptors.Br J Pharmacol 1998 Dec; 125:1761-7.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Pitzalis MV, De Tommasi E, Rizzon B et al. Beneficial effect of valsartan but not enalapril on sympathetic system activation in heartfailure. Citation: Eur Heart J September 2001; 22 (suppl): Abstr. 40.</mixed-citation><mixed-citation xml:lang="en">Pitzalis MV, De Tommasi E, Rizzon B et al. Beneficial effect of valsartan but not enalapril on sympathetic system activation in heartfailure. Citation: Eur Heart J September 2001; 22 (suppl): Abstr. 40.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
